Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival

Miyuki Tsuchihashi-Makaya, Shintaro Kinugawa, Hisashi Yokoshiki, Sanae Hamaguchi, Takashi Yokota, Daisuke Goto, Kazutomo Goto, Akira Takeshita, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Previous studies demonstrated that β-blocker use at the time of hospital discharge significantly increased postdischarge treatment rates, associated with an early (60- to 90-day) survival benefit in patients with heart failure (HF). However, it is unknown whether this therapeutic approach can also improve the long-term survival. We thus examined the long-term effects of β-blocker use at discharge on outcomes in patients hospitalized for HF and left ventricular systolic dysfunction (LVSD) (ejection fraction <40%). Methods and Results: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) enrolled HF patients hospitalized with worsening symptoms and they were followed during an average of 2.2 years. A total of 947 patients had LVSD, among whom 624 (66%) were eligible to receive a β-blocker at discharge. After adjustment for covariate and propensity score, discharge use of β-blocker, when compared to no β-blocker use, was associated with a significant reduced risk of all-cause mortality (hazard ratio (HR) 0.564, 95% confidence interval (CI) 0.358-0.889, P=0.014) and cardiac mortality (HR 0.489, 95%CI 0.279-0.859, P=0.013) after hospital discharge. Conclusions: β-blocker use at the time of discharge was associated with a long-term survival benefit in a diverse cohort of patients hospitalized with HF.

Original languageEnglish
Pages (from-to)1364-1371
Number of pages8
JournalCirculation Journal
Volume74
Issue number7
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

Patient Discharge
Heart Failure
Survival
Left Ventricular Dysfunction
Confidence Intervals
Propensity Score
Mortality
Cardiology
Registries
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. / Tsuchihashi-Makaya, Miyuki; Kinugawa, Shintaro; Yokoshiki, Hisashi; Hamaguchi, Sanae; Yokota, Takashi; Goto, Daisuke; Goto, Kazutomo; Takeshita, Akira; Tsutsui, Hiroyuki.

In: Circulation Journal, Vol. 74, No. 7, 01.01.2010, p. 1364-1371.

Research output: Contribution to journalArticle

Tsuchihashi-Makaya, M, Kinugawa, S, Yokoshiki, H, Hamaguchi, S, Yokota, T, Goto, D, Goto, K, Takeshita, A & Tsutsui, H 2010, 'Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival', Circulation Journal, vol. 74, no. 7, pp. 1364-1371. https://doi.org/10.1253/circj.CJ-09-0993
Tsuchihashi-Makaya M, Kinugawa S, Yokoshiki H, Hamaguchi S, Yokota T, Goto D et al. Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circulation Journal. 2010 Jan 1;74(7):1364-1371. https://doi.org/10.1253/circj.CJ-09-0993
Tsuchihashi-Makaya, Miyuki ; Kinugawa, Shintaro ; Yokoshiki, Hisashi ; Hamaguchi, Sanae ; Yokota, Takashi ; Goto, Daisuke ; Goto, Kazutomo ; Takeshita, Akira ; Tsutsui, Hiroyuki. / Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. In: Circulation Journal. 2010 ; Vol. 74, No. 7. pp. 1364-1371.
@article{fa4a0cfa0a7148e9b055f84f598bc95b,
title = "Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival",
abstract = "Background: Previous studies demonstrated that β-blocker use at the time of hospital discharge significantly increased postdischarge treatment rates, associated with an early (60- to 90-day) survival benefit in patients with heart failure (HF). However, it is unknown whether this therapeutic approach can also improve the long-term survival. We thus examined the long-term effects of β-blocker use at discharge on outcomes in patients hospitalized for HF and left ventricular systolic dysfunction (LVSD) (ejection fraction <40{\%}). Methods and Results: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) enrolled HF patients hospitalized with worsening symptoms and they were followed during an average of 2.2 years. A total of 947 patients had LVSD, among whom 624 (66{\%}) were eligible to receive a β-blocker at discharge. After adjustment for covariate and propensity score, discharge use of β-blocker, when compared to no β-blocker use, was associated with a significant reduced risk of all-cause mortality (hazard ratio (HR) 0.564, 95{\%} confidence interval (CI) 0.358-0.889, P=0.014) and cardiac mortality (HR 0.489, 95{\%}CI 0.279-0.859, P=0.013) after hospital discharge. Conclusions: β-blocker use at the time of discharge was associated with a long-term survival benefit in a diverse cohort of patients hospitalized with HF.",
author = "Miyuki Tsuchihashi-Makaya and Shintaro Kinugawa and Hisashi Yokoshiki and Sanae Hamaguchi and Takashi Yokota and Daisuke Goto and Kazutomo Goto and Akira Takeshita and Hiroyuki Tsutsui",
year = "2010",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-09-0993",
language = "English",
volume = "74",
pages = "1364--1371",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "7",

}

TY - JOUR

T1 - Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival

AU - Tsuchihashi-Makaya, Miyuki

AU - Kinugawa, Shintaro

AU - Yokoshiki, Hisashi

AU - Hamaguchi, Sanae

AU - Yokota, Takashi

AU - Goto, Daisuke

AU - Goto, Kazutomo

AU - Takeshita, Akira

AU - Tsutsui, Hiroyuki

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Previous studies demonstrated that β-blocker use at the time of hospital discharge significantly increased postdischarge treatment rates, associated with an early (60- to 90-day) survival benefit in patients with heart failure (HF). However, it is unknown whether this therapeutic approach can also improve the long-term survival. We thus examined the long-term effects of β-blocker use at discharge on outcomes in patients hospitalized for HF and left ventricular systolic dysfunction (LVSD) (ejection fraction <40%). Methods and Results: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) enrolled HF patients hospitalized with worsening symptoms and they were followed during an average of 2.2 years. A total of 947 patients had LVSD, among whom 624 (66%) were eligible to receive a β-blocker at discharge. After adjustment for covariate and propensity score, discharge use of β-blocker, when compared to no β-blocker use, was associated with a significant reduced risk of all-cause mortality (hazard ratio (HR) 0.564, 95% confidence interval (CI) 0.358-0.889, P=0.014) and cardiac mortality (HR 0.489, 95%CI 0.279-0.859, P=0.013) after hospital discharge. Conclusions: β-blocker use at the time of discharge was associated with a long-term survival benefit in a diverse cohort of patients hospitalized with HF.

AB - Background: Previous studies demonstrated that β-blocker use at the time of hospital discharge significantly increased postdischarge treatment rates, associated with an early (60- to 90-day) survival benefit in patients with heart failure (HF). However, it is unknown whether this therapeutic approach can also improve the long-term survival. We thus examined the long-term effects of β-blocker use at discharge on outcomes in patients hospitalized for HF and left ventricular systolic dysfunction (LVSD) (ejection fraction <40%). Methods and Results: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) enrolled HF patients hospitalized with worsening symptoms and they were followed during an average of 2.2 years. A total of 947 patients had LVSD, among whom 624 (66%) were eligible to receive a β-blocker at discharge. After adjustment for covariate and propensity score, discharge use of β-blocker, when compared to no β-blocker use, was associated with a significant reduced risk of all-cause mortality (hazard ratio (HR) 0.564, 95% confidence interval (CI) 0.358-0.889, P=0.014) and cardiac mortality (HR 0.489, 95%CI 0.279-0.859, P=0.013) after hospital discharge. Conclusions: β-blocker use at the time of discharge was associated with a long-term survival benefit in a diverse cohort of patients hospitalized with HF.

UR - http://www.scopus.com/inward/record.url?scp=77954484555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954484555&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-09-0993

DO - 10.1253/circj.CJ-09-0993

M3 - Article

VL - 74

SP - 1364

EP - 1371

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 7

ER -